American journal of surgery · 2023
Trends in adoption of total neoadjuvant therapy for locally advanced rectal cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Unuvar Maria, Blansfield Joseph, Wang Shengxuan, Hoffman Rebecca L
Аннотация
BACKGROUND: Total neoadjuvant chemoradiation (TNT), an accepted strategy for the treatment of locally advanced rectal cancer (LARC), was first included in guidelines in 2018. We aimed to describe trends in, and factors associated with TNT receipt.
METHODS: A retrospective cohort study of adult patients with LARC was performed using the national cancer database (2012-2020). TNT status was determined, and temporal trends analyzed. Factors associated with TNT receipt were identified by stage.
RESULTS: A total of 51,407 patients were identified; 57.3 % received TNT. Increasing age and comorbidities were associated with higher rates of TNT receipt. Patients with stage III disease were more likely to receive TNT (stage II OR 0.92, 95%CI 0.88-0.96). Patients were 38 % more likely to get TNT after guideline inclusion (OR1.38, 95%CI 1.31-1.46).
CONCLUSION: Rates of TNT were consistently above 50 % and rose after inclusion in the NCCN guidelines. This study establishes baseline patterns in rates of TNT for future benchmarking.
METHODS: A retrospective cohort study of adult patients with LARC was performed using the national cancer database (2012-2020). TNT status was determined, and temporal trends analyzed. Factors associated with TNT receipt were identified by stage.
RESULTS: A total of 51,407 patients were identified; 57.3 % received TNT. Increasing age and comorbidities were associated with higher rates of TNT receipt. Patients with stage III disease were more likely to receive TNT (stage II OR 0.92, 95%CI 0.88-0.96). Patients were 38 % more likely to get TNT after guideline inclusion (OR1.38, 95%CI 1.31-1.46).
CONCLUSION: Rates of TNT were consistently above 50 % and rose after inclusion in the NCCN guidelines. This study establishes baseline patterns in rates of TNT for future benchmarking.